Back to News
Market Impact: 0.2

We're starting positions in 2 more defensive stocks to balance our AI exposure

Source: CNBC

+2
Banking & LiquidityCorporate Guidance & OutlookCompany FundamentalsCapital Returns (Dividends / Buybacks)M&A & RestructuringInterest Rates & YieldsElections & Domestic Politics
We're starting positions in 2 more defensive stocks to balance our AI exposure

The article initiates two new portfolio positions: BNY (240 shares at ~$161) and Kimberly-Clark (365 shares at ~$108), targeting ~$180 for BNY (17.5x 2027E EPS) and ~$120 for KMB (16x 2027E EPS). The manager cites a defensive tilt ahead of a potential September Fed hike (higher discount rates compress P/Es) and argues BNY’s fee-based model limits exposure to the credit cycle, while KMB’s pending Kenvue deal (expected to close before year-end) adds scale plus $1.9B cost synergies and a ~4.75% dividend yield.

Analysis

The real signal is factor rotation, not the individual names: the portfolio is trading away long-duration AI capex exposure and into cash-flow compounding with lower earnings beta. That tends to help asset-light financial infrastructure like BNY more than traditional lenders, because the market can re-rate fee stability without needing a steepening yield curve or loan growth. BK is the closest competitive watch item: if BNY keeps taking operating leverage out of custody/clearing, the sector may bifurcate toward the best execution and away from the balance-sheet banks.

For BNY, the near-term setup is less about a rate hike itself than about investors paying up for visible mid-teens EPS growth and margin discipline while deposit franchises get compressed elsewhere. The risk is that this becomes a crowded defensives trade; if the Fed blinks or equity volumes/asset values soften, the market could rotate back into cyclicals and leave BNY’s multiple stuck. A break below the low-$150s would likely signal the market is no longer rewarding quality/defensiveness.

KMB is a different story: the catalyst is not the dividend but whether the Kenvue deal converts a mature staples compounder into a higher-quality health-and-wellness platform. The market is likely underpricing integration friction, litigation noise, and the balance-sheet drag needed to fund the transaction; that means the rerating may be slower than headline synergies imply. If management does not show clear cost takeout and leverage reduction within 1-2 quarters post-close, the valuation gap to PG may persist or widen.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.25

Ticker Sentiment

BK0.00
BNY0.45
FCD.UN.TO0.00
KMB0.35
OZK0.00
PG0.00
TGT0.00
TSTS0.00
TUEMQ0.00
WFC0.00

Key Decisions for Investors

  • Long BNY / short WFC for 1-3 months into the Fed meeting: express the view that fee-based custody/asset servicing outperforms deposit-beta banks in a higher-rate, lower-multiple regime. Falsifier: a dovish pivot or sharp curve steepening that re-accelerates WFC NII expectations.
  • Buy KMB on weakness or use a 3-6 month call spread; the upside is a modest multiple rerate if synergy delivery is credible, but the position should be sized for slower realization. Falsifier: deal financing/leverage comes in meaningfully worse than expected or litigation headlines intensify.
  • Pair trade: long KMB / short PG into the first post-close update if KMB can show faster earnings growth from Kenvue than the market is modeling. Risk/reward is attractive only if KMB demonstrates integration progress; otherwise PG remains the cleaner quality staple.
  • Set an alert on BNY if it loses its premium multiple despite stable earnings revisions; that would be the signal that the defensive rotation has become overextended and the entry point is no longer favorable.

More News